Illumina introduced three early-access AI-driven capabilities on its BioInsight Platform—DRAGEN Ultra, Workflow Orchestrator, and Learning Cohorts—to accelerate genomic research. These tools automate sequencing workflows, prioritize genetic variants using AI models, and enable researchers to analyze large genomic and multiomic datasets in context. This innovation aims to help labs scale operations efficiently and focus on meaningful discoveries in genetics and disease research. The new features are available now for early access customers and were unveiled at the American Society of Human Genetics meeting.
Illumina, Inc. holds a market cap of $40.46 billion and an enterprise value of $41.82 billion as of Oct 21, 2026, 20:23 WIB. The stock price on Pluang is USD 264.00, down 1.47% for the day, reflecting some investor caution despite the launch of new AI-driven capabilities on its BioInsight Platform. Trading volume stands at 1,584,171 shares, with a typical hold time of 84 days, indicating steady investor interest in this health sector stock.
